Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Zürich

Precision In Clinical Trials Summit Zurich- Europe

The clinical trial industry in Zurich has experienced significant growth and established prominence, solidifying the city's reputation as a vital hub for cutting-edge medical research [...]

Go to Top